TGFBR2 and neoplasm: This strategy which is considered generally feasible, despite no partial response being observed in the study, and safe, with study-related serious adverse events mostly being cytokine release syndrome, warrants further validation and investigation.1006 Dominant-negative TβRII can also enhance the anti-tumor efficacy of DC vaccines, manifested by powerful tumor-specific CTL responses, inhibited tumor development, and prolonged survival times in mouse models.1007,1008 Moreover, dominant-negative TβRII showed great potential for reducing hypertrophic scars as in rabbit ear models.1009